Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?

• Jacob E Choby,
• Tugba Ozturk,
• Sarah W Satola,
• Jesse T Jacob,
• David S Weiss

Affiliations

Jacob E Choby

Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA

Tugba Ozturk

Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA

Sarah W Satola

Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Programme, Atlanta, GA, USA

Jesse T Jacob

Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Programme, Atlanta, GA, USA

David S Weiss

Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA